Hyperalgesia - Pipeline Review, H1 2020

January 2020 | 39 pages | ID: HE09AB36E60EN
Global Markets Direct

Abstracts

Hyperalgesia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperalgesia - Pipeline Review, H1 2020, provides an overview of the Hyperalgesia (Central Nervous System) pipeline landscape.

Hyperalgesia is an increase in pain response. Predisposing factors include long term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves and psychological disorders. Treatment includes antidepressants and Non-steroidal anti-inflammatory drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperalgesia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Hyperalgesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperalgesia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Hyperalgesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hyperalgesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hyperalgesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hyperalgesia (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hyperalgesia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hyperalgesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hyperalgesia - Overview
Hyperalgesia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperalgesia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperalgesia - Companies Involved in Therapeutics Development
Cara Therapeutics Inc
Caventure Drug Discovery Inc
Charleston Laboratories Inc
Exodos Life Sciences Limited Partnership
H. Lundbeck AS
Novartis AG
Hyperalgesia - Drug Profiles
ABX-1431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperalgesia - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hyperalgesia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hyperalgesia - Pipeline by Cara Therapeutics Inc, H1 2020
Hyperalgesia - Pipeline by Caventure Drug Discovery Inc, H1 2020
Hyperalgesia - Pipeline by Charleston Laboratories Inc, H1 2020
Hyperalgesia - Pipeline by Exodos Life Sciences Limited Partnership, H1 2020
Hyperalgesia - Pipeline by H. Lundbeck AS, H1 2020
Hyperalgesia - Pipeline by Novartis AG, H1 2020
Hyperalgesia - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hyperalgesia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Cara Therapeutics Inc
Caventure Drug Discovery Inc
Charleston Laboratories Inc
Exodos Life Sciences Limited Partnership
H. Lundbeck AS
Novartis AG